Vascular Dysfunction in Obese Diabetic Db/db Mice Involves the Interplay Between Aldosterone/mineralocorticoid Receptor and Rho Kinase Signaling
Authors
Affiliations
Activation of aldosterone/mineralocorticoid receptors (MR) has been implicated in vascular dysfunction of diabetes. Underlying mechanisms are elusive. Therefore, we investigated the role of Rho kinase (ROCK) in aldosterone/MR signaling and vascular dysfunction in a model of diabetes. Diabetic obese mice (db/db) and control counterparts (db/+) were treated with MR antagonist (MRA, potassium canrenoate, 30 mg/kg/day, 4 weeks) or ROCK inhibitor, fasudil (30 mg/kg/day, 3 weeks). Plasma aldosterone was increased in db/db versus db/+. This was associated with enhanced vascular MR signaling. Norepinephrine (NE)-induced contraction was increased in arteries from db/db mice. These responses were attenuated in mice treated with canrenoate or fasudil. Db/db mice displayed hypertrophic remodeling and increased arterial stiffness, improved by MR blockade. Vascular calcium sensitivity was similar between depolarized arteries from db/+ and db/db. Vascular hypercontractility in db/db mice was associated with increased myosin light chain phosphorylation and reduced expression of PKG-1α. Vascular RhoA/ROCK signaling and expression of pro-inflammatory and pro-fibrotic markers were exaggerated in db/db mice, effects that were attenuated by MRA. Fasudil, but not MRA, improved vascular insulin sensitivity in db/db mice, evidenced by normalization of Irs1 phosphorylation. Our data identify novel pathways involving MR-RhoA/ROCK-PKG-1 that underlie vascular dysfunction and injury in diabetic mice.
Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.
Qi Y, Ma Y, Duan G Int J Mol Sci. 2025; 25(24.
PMID: 39769418 PMC: 11727972. DOI: 10.3390/ijms252413656.
Dourado T, Nascimento D, Rosa M, Assis V, Pimenta G, Alves-Filho J Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1707-1720.
PMID: 39172146 DOI: 10.1007/s00210-024-03382-3.
The Role of Rho Kinase Inhibitors in Corneal Diseases.
Futterknecht S, Chatzimichail E, Gugleta K, Panos G, Gatzioufas Z Drug Des Devel Ther. 2024; 18:97-108.
PMID: 38264539 PMC: 10804875. DOI: 10.2147/DDDT.S435522.
Barbosa G, Costa R, Awata W, Singh S, Alves J, Bruder-Nascimento A Biosci Rep. 2023; 43(7).
PMID: 37342890 PMC: 10352127. DOI: 10.1042/BSR20230672.
Jimenez-Castilla L, Opazo-Rios L, Marin-Royo G, Orejudo M, Rodrigues-Diez R, Ballesteros-Martinez C Antioxidants (Basel). 2022; 11(12).
PMID: 36552707 PMC: 9774734. DOI: 10.3390/antiox11122499.